Elizabeth Dees
Breast Oncology & Phase I Trials Section Chief · University of North Carolina Hospitals
Credentials: · · · ·
History
- 1999–2002
Johns Hopkins Oncology Center
- 1996–1999
1989–1993- 1985–1989
Research
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2018 · 1,827 citations
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
Clinical Cancer Research · 2007 · 1,643 citations
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Journal of Clinical Oncology · 2016 · 1,239 citations
37 papers
14 papers
13 papers
12 papers · 6 as a resident
12 papers
11 papers
11 papers
Christine Walko
8 papers
Grants
- 2019–2027
UNC Lead Academic Participating Site
National Cancer Institute · UG1
PI · $454.7K · Univ of North Carolina Chapel Hill
- 2014–2023
National Cancer Institute · UM1
PI · $6.8M · Duke University
- 2006–2009
Phase I Radiosensitization Study of GW572016 in Recurrent Breast Cancer
National Cancer Institute · R21
Contact PI · $403.5K · Univ of North Carolina Chapel Hill
- 2003–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $64.5K · Univ of North Carolina Chapel Hill
Clinical trials
- 2019–2022
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
National Cancer Institute (NCI)
- 2016–2023
Principal investigator · Completed · Phase 2
UNC Lineberger Comprehensive Cancer Center
- 2015–2017
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Principal investigator · Terminated · Phase 1, Phase 2
NewLink Genetics Corporation
- 2007–2011
Principal investigator · Completed · Phase 1
UNC Lineberger Comprehensive Cancer Center